Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period

A. Lauro; A. Amaduzzi; A. Dazzi; G. Ercolani; C. Zanfi; L. Golfieri; G. L. Grazi; M. Vivarelli; M. Cescon; G. Varotti; M. Del Gaudio; M. Ravaioli; A. Siniscalchi; S. Faenza; A. D'Errico; M. Di Simone; L. Pironi; A. D. Pinna

doi:10.1016/j.dld.2006.11.012

Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period

A. Lauro, A. Amaduzzi, A. Dazzi, G. Ercolani, C. Zanfi, L. Golfieri, G. L. Grazi, M. Vivarelli, M. Cescon, G. Varotti, M. Del Gaudio, M. Ravaioli, A. Siniscalchi, S. Faenza, A. D'Errico, M. Di Simone, L. Pironi, A. D. Pinna

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Induction therapy has been recently adopted for intestinal transplant. Patients and methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax^®) or Alemtuzumab (Campath-1H^®). Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection. Discussion and conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.

Original language	English
Pages (from-to)	253-256
Number of pages	4
Journal	Digestive and Liver Disease
Volume	39
Issue number	3
DOIs	https://doi.org/10.1016/j.dld.2006.11.012
Publication status	Published - Mar 2007

Keywords

Alemtuzumab
Daclizumab
Immunosuppression
Induction therapy

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.dld.2006.11.012

Fingerprint Dive into the research topics of 'Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period'. Together they form a unique fingerprint.

Cite this

Lauro, A., Amaduzzi, A., Dazzi, A., Ercolani, G., Zanfi, C., Golfieri, L., Grazi, G. L., Vivarelli, M., Cescon, M., Varotti, G., Del Gaudio, M., Ravaioli, M., Siniscalchi, A., Faenza, S., D'Errico, A., Di Simone, M., Pironi, L., & Pinna, A. D. (2007). Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period. Digestive and Liver Disease, 39(3), 253-256. https://doi.org/10.1016/j.dld.2006.11.012

Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation : A comparison of two different regimens on 29 recipients during the early post-operative period. / Lauro, A.; Amaduzzi, A.; Dazzi, A.; Ercolani, G.; Zanfi, C.; Golfieri, L.; Grazi, G. L.; Vivarelli, M.; Cescon, M.; Varotti, G.; Del Gaudio, M.; Ravaioli, M.; Siniscalchi, A.; Faenza, S.; D'Errico, A.; Di Simone, M.; Pironi, L.; Pinna, A. D.

In: Digestive and Liver Disease, Vol. 39, No. 3, 03.2007, p. 253-256.

Research output: Contribution to journal › Article › peer-review

Lauro, A, Amaduzzi, A, Dazzi, A, Ercolani, G, Zanfi, C, Golfieri, L, Grazi, GL, Vivarelli, M, Cescon, M, Varotti, G, Del Gaudio, M, Ravaioli, M, Siniscalchi, A, Faenza, S, D'Errico, A, Di Simone, M, Pironi, L & Pinna, AD 2007, 'Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period', Digestive and Liver Disease, vol. 39, no. 3, pp. 253-256. https://doi.org/10.1016/j.dld.2006.11.012

Lauro, A. ; Amaduzzi, A. ; Dazzi, A. ; Ercolani, G. ; Zanfi, C. ; Golfieri, L. ; Grazi, G. L. ; Vivarelli, M. ; Cescon, M. ; Varotti, G. ; Del Gaudio, M. ; Ravaioli, M. ; Siniscalchi, A. ; Faenza, S. ; D'Errico, A. ; Di Simone, M. ; Pironi, L. ; Pinna, A. D. / Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation : A comparison of two different regimens on 29 recipients during the early post-operative period. In: Digestive and Liver Disease. 2007 ; Vol. 39, No. 3. pp. 253-256.

@article{4e8c42baa0294b9b81ba5a6174db91f9,

title = "Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period",

abstract = "Introduction: Induction therapy has been recently adopted for intestinal transplant. Patients and methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax{\textregistered}) or Alemtuzumab (Campath-1H{\textregistered}). Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection. Discussion and conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.",

keywords = "Alemtuzumab, Daclizumab, Immunosuppression, Induction therapy",

author = "A. Lauro and A. Amaduzzi and A. Dazzi and G. Ercolani and C. Zanfi and L. Golfieri and Grazi, {G. L.} and M. Vivarelli and M. Cescon and G. Varotti and {Del Gaudio}, M. and M. Ravaioli and A. Siniscalchi and S. Faenza and A. D'Errico and {Di Simone}, M. and L. Pironi and Pinna, {A. D.}",

year = "2007",

month = mar,

doi = "10.1016/j.dld.2006.11.012",

language = "English",

volume = "39",

pages = "253--256",

journal = "Digestive and Liver Disease",

issn = "1590-8658",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation

T2 - A comparison of two different regimens on 29 recipients during the early post-operative period

AU - Lauro, A.

AU - Amaduzzi, A.

AU - Dazzi, A.

AU - Ercolani, G.

AU - Zanfi, C.

AU - Golfieri, L.

AU - Grazi, G. L.

AU - Vivarelli, M.

AU - Cescon, M.

AU - Varotti, G.

AU - Del Gaudio, M.

AU - Ravaioli, M.

AU - Siniscalchi, A.

AU - Faenza, S.

AU - D'Errico, A.

AU - Di Simone, M.

AU - Pironi, L.

AU - Pinna, A. D.

PY - 2007/3

Y1 - 2007/3

N2 - Introduction: Induction therapy has been recently adopted for intestinal transplant. Patients and methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax®) or Alemtuzumab (Campath-1H®). Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection. Discussion and conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.

AB - Introduction: Induction therapy has been recently adopted for intestinal transplant. Patients and methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax®) or Alemtuzumab (Campath-1H®). Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection. Discussion and conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.

KW - Alemtuzumab

KW - Daclizumab

KW - Immunosuppression

KW - Induction therapy

UR - http://www.scopus.com/inward/record.url?scp=33846709767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846709767&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2006.11.012

DO - 10.1016/j.dld.2006.11.012

M3 - Article

C2 - 17275428

AN - SCOPUS:33846709767

VL - 39

SP - 253

EP - 256

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 3

ER -